KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.

Min He, Yi-Zhou Jiang, Yue Gong, Lei Fan, Xi-Yu Liu, Yin Liu, Li-Chen Tang, Miao Mo, Yi-Feng Hou, Gen-Hong Di, Guang-Yu Liu, Ke-Da Yu, Jiong Wu, Xia Yan, Xiao-Hua Zeng, De-Yuan Fu, Chuan-Gui Song, Zhi-Gang Zhuang, Ke-Jin Wu, Jie Wang, Zhong-Hua Wang, Zhi-Ming Shao

BMJ 387 e079603

PMID39442958
PMCIDPMC11497771
DOI10.1136/bmj-2024-079603
发表日期2024-10-23
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

OBJECTIVE: To evaluate the feasibility of using a multigene signature to tailor individualised adjuvant therapy for patients with operable triple negative breast cancer. DESIGN: Randomised, multicentre, open label, phase 3 trial. SETTING: 7 cancer centres in China between 3 January 2016 and 17 July 2023. PARTICIPANTS: Female patients aged 18-70 years with early triple negative breast cancer after definitive surgery. INTERVENTIONS: After risk stratification using the integrated signature, patients at high risk were randomised (1:1) to receive an intensive adjuvant treatment comprising four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (arm A; n=166) or a standard treatment of four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (arm B; n=170). Patients at low risk received the same adjuvant chemotherapy as arm B (arm C; n=168). MAIN OUTCOME MEASURES: The primary endpoint was disease-free survival in the intention-to-treat analysis for arm A versus arm B. Secondary endpoints included disease-free survival for arm C versus arm B, recurrence-free survival, overall survival, and safety. RESULTS: Among the 504 enrolled patients, 498 received study treatment. At a median follow-up of 45.1 months, the three year disease-free survival rate was 90.9% for patients in arm A and 80.6% for patients in arm B (hazard ratio 0.51, 95% confidence interval (CI) 0.28 to 0.95; P=0.03). The three year recurrence-free survival rate was 92.6% in arm A and 83.2% in arm B (hazard ratio 0.50, 95% CI 0.25 to 0.98; P=0.04). The three year overall survival rate was 98.2% in arm A and 91.3% in arm B (hazard ratio 0.58, 95% CI 0.22 to 1.54; P=0.27). The rates of disease-free survival (three year disease-free survival 90.1% v 80.6%; hazard ratio 0.57, 95% CI 0.33 to 0.98; P=0.04), recurrence-free survival (three year recurrence-free survival 94.5% v 83.2%; 0.42, 0.22 to 0.81; P=0.007), and overall survival (three year overall survival 100% v 91.3%; 0.14, 0.03 to 0.61; P=0.002) were significantly higher in patients in arm C than in those in arm B with the same chemotherapy regimen. The incidence of grade 3-4 treatment related adverse events were 64% (105/163), 51% (86/169), and 54% (90/166) for arms A, B, and C, respectively. No treatment related deaths occurred. CONCLUSIONS: The multigene signature showed potential for tailoring adjuvant chemotherapy for patients with operable triple negative breast cancer. Intensive regimens incorporating gemcitabine and cisplatin into anthracycline/taxane based therapy significantly improved disease-free survival with manageable toxicity. TRIAL REGISTRATION: ClinicalTrials.gov NCT02641847.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig 2

Fig 2 Clinical outcomes among patients with high risk score. Kaplan-Meier plots show disease-free survival (top), recurrence-free survival (middle), and overall survival (bottom) for patients with high risk score. EC-T=epirubicin and cyclophosphamide followed by docetaxel; TEC-GP=docetaxel, epirubicin, and cyclophosphamide followed by gemcitabine and cisplatin

Disease-free_survival_top_

Disease-free survival

Fig 2 · Panel Disease-free_survival_top_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Disease-free_survival_top_ 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Recurrence-free_survival_middle_

Recurrence-free survival

Fig 2 · Panel Recurrence-free_survival_middle_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Recurrence-free_survival_middle_ 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Overall_survival_bottom_

Overall survival

Fig 2 · Panel Overall_survival_bottom_

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival_bottom_ 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1 Flowchart of study. *Unspecified reasons. EC-T=epirubicin and cyclophosphamide followed by docetaxel; ITT-intention-to-treat; TEC-GP=docetaxel, epirubicin, and cyclophosphamide followed by gemcitabine and cisplatin
非 KM Figure
Fig 3Fig 3 Exploratory subgroup analyses for disease-free survival among patients with high risk score. CI=confidence interval; EC-T=epirubicin and cyclophosphamide followed by docetaxel; TEC-GP=docetaxel, epirubicin, and cyclophosphamide followed by gemcitabine and cisplatin
非 KM Figure